Since November 2016, we entered into various manufacturing services agreements with WuXi Advanced Therapies, Inc., and its parent company WuXi Apptec, Co. Ltd, or collectively, WuXi, pursuant to whic…
Since November 2016, we entered into various manufacturing services agreements with WuXi Advanced Therapies, Inc., and its parent company WuXi Apptec, Co. Ltd, or collectively, WuXi, pursuant to whic…
The Company paid an upfront payment to Novartis and may pay future milestones related to initiation of patient dosing in various phases of clinical development for IOV-3001 and approval of the produc…
The Company will license gene-editing technology from Cellectis S.A. to develop TIL cell therapies that have been genetically edited, including a PD-1 inactivated product that the Company refers to a…
Reciprocal relationship from CLLS graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from IOVA graph: The Company will license gene-editi…
The Company entered into a patent license agreement with the NIH, an agency of the U.S. Public Health Service within the Department of Health and Human Services, in 2011.
Reciprocal relationship from CRBU graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the…
Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial.…
NOTE 4. PROLEUKIN ® ACQUISITION On January 23, 2023, the Company and its newly formed, wholly owned subsidiary, Iovance Biotherapeutics UK Ltd (the “Purchaser”) entered into an Option Agreement (the …
NOTE 4. PROLEUKIN ® ACQUISITION On January 23, 2023, the Company and its newly formed wholly owned subsidiary, Iovance Biotherapeutics UK Ltd (the “Purchaser”) entered into an Option Agreement (the “…
nter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the produ…
Reciprocal relationship from CRBU graph: untries where our product candidates may be sold at lower prices than in the United States. Third-party payors, whether domestic or foreign, governmental or c…
Reciprocal relationship from GNLX graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX g…
Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…
Iovance Biotherapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IOVA-DEBT-10333
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
IOVA-DEBT
Debt stack $47.8M
90%
Market cache reports total debt of $47.8M.
IOVA-DEBT-10332
Warrants outstanding: 15754000
90%
xbrl warrant detail from xbrl 2018-12-31.
Iovance Biotherapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Iovance Biotherapeutics, Inc..
Iovance Biotherapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
IOVA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 289 tracked holders.
Iovance Biotherapeutics, Inc. Extended Supply Chain Network
